RevenueShares Ultra Dividend ETF

Most Recent

  • uploads///Elacestrant market opportunity
    Company & Industry Overviews

    Taking Stock of Radius Health’s Licensing Agreements

    The market has responded very positively to Radius Health’s recent performance. In the past month, Radius stock has generated a 28% return for its shareholders.

    By Kenneth Smith
  • uploads///RDUS pipeline
    Company & Industry Overviews

    A Strong Pipeline of Drugs Bodes Well for Radius Health

    The drug candidates in Radius Health’s (RDUS) pipeline include an investigational abaloparatide transdermal patch for possible use in treating women with postmenopausal osteoporosis.

    By Kenneth Smith
  • uploads///RDUS Analysts Reco
    Company & Industry Overviews

    Analysts’ Ratings for Radius Health and Its Peers in January

    In April 2017, Radius received FDA approval for its first commercial product, Tymlos. Tymlos was approved for the treatment of postmenopausal women with osteoporosis at a high risk for fracture.

    By Kenneth Smith
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.